A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Trial Profile

A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Napabucasin (Primary) ; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 05 Jun 2018 Results assessing safety and efficacy of napabucasin plus paclitaxel in patients with thymoma and thymic carcinoma (n=16) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 01 Jun 2018 According to a Boston Biomedical media release, results (n=16) from phase 1b part of the study are available online publication.
    • 17 May 2018 According to the Sumitomo Dainippon Pharma media release, data from this study will be presented at at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top